AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies (AIT Ltd.), an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of Continue reading AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Vertex Pharmaceuticals Incorporated : Patent Issued for Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

http://www.4-traders.com/VERTEX-PHARMACEUTICALS-IN-11321/news/Vertex-Pharmaceuticals-Incorporated–Patent-Issued-for-Modulators-of-Cystic-Fibrosis-Transmembrane-17743040/

By a News Reporter-Staff News Editor at Diabetes Week — A patent by the inventors Yang, Xiaoqing (San Diego, CA); Hadida Ruah, Sara Sabina (La Jolla, CA); Grootenhuis, Peter Diederik Jan (San Diego, CA); Continue reading Vertex Pharmaceuticals Incorporated : Patent Issued for Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

Potential new drug target for cystic fibrosis

 Large-scale screen also identified genes not previously linked to the disease
http://www.thealmagest.com/potential-new-drug-target-cystic-fibrosis/3775

Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a Continue reading Potential new drug target for cystic fibrosis

Connect, Share, Inform, Unite. Live event: (Sex), Drugs & Rock’n’Roll

The transition years – adherence and living independently with CF
In the first of two linked live events, Dr Alistair Duff (Consultant Clinical Psychologist at St James’ Hospital, Leeds) chairs an event that will discuss the big challenges of growing up with CF – taking Continue reading Connect, Share, Inform, Unite. Live event: (Sex), Drugs & Rock’n’Roll

Cost of cystic fibrosis drug, others threatens system, doctors say

At a cost of more than $300,000 a year, the new cystic fibrosis drug, Kalydeco, is one of the most expensive pills in American medicine. In early October, three doctors who treat cystic fibrosis patients said that kind of extremely high pricing for new drugs that treat rare conditions threatens the U.S. health care system and can’t be sustained.

Continue reading Cost of cystic fibrosis drug, others threatens system, doctors say

KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status

KaloBios Pharmaceuticals Inc. (KBIO) said the U.S. Food and Drug Administration granted orphan-drug designation for its treatment for cystic fibrosis patients with Pseudomonas aeruginosa. Continue reading KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status

Teva announces FDA approval of generic TOBI in the United States

JERUSALEM–(BUSINESS WIRE)–Oct. 14, 2013– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI┬« (Tobramycin Inhalation Solution Continue reading Teva announces FDA approval of generic TOBI in the United States

Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients

Pharmaceutical discovery and development company Celtaxsys, Inc. today announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis (CF) patients. In this study, the safety and Continue reading Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients

Why AbbVie’s Global Alliance With Galapagos Is Good News for Investors

Since becoming an independent company late last year, AbbVie has been making significant progress. AbbVie shares have been among the best performers in the health care sector this year, gaining nearly 31% year-to-date. The gains have come Continue reading Why AbbVie’s Global Alliance With Galapagos Is Good News for Investors

If Chosen Wisely, Existing Drugs Fight Resistant Bugs

Science/AAAS | News
Fatal weakness. Pathogens such as methicillin-resistant Staphylococcus aureus (above) develop vulnerabilities as they evolve resistance to antibiotics. Choosing antibiotics that exploit these weaknesses can thwart resistant bacteria. Continue reading If Chosen Wisely, Existing Drugs Fight Resistant Bugs